Back to results
US 2018/0000797 A1Published application
Oct3 activity inhibitor containing imidazopyridine derivative as active component, and oct3 detection agent
AssigneeShin Nippon Biomedical Laboratories, Ltd.
InventorsHidetoshi YAMASHITA, Nobuyuki Suzuki
Life of this patent
Estimating the term…
Abstract
To provide an OCT3 activity inhibitor having a different basic skeleton than that of conventional OCT3 activity inhibitors. This inhibitor of organic cation transporter 3 (OCT3) contains, as an active component, an imidazo[1,2-a]pyridine derivative, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof.
Claims6
A method of inhibit an organic cation transporter 3 (OCT3) containing:
- administrating an OCT3 inhibitor represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, as an active component, to an object to inhibit an OCT3,
- in formula (I),
- R1 to R3, R5 and R6 can be the same or different, and
- each represent a hydrogen atom, a halogen atom, a C1-3 alkyl group, a C1-3 alkoxy group, a C1-3 alkylthio group, or a C1-3 halogenoalkyl group, and
- R4 represents any of the groups represented by formulae (II) to (III),
- in formula (II),
- X2 represents selected from a C1-10 alkyl group which can have a substituent, a C1-10 alkoxy group which can have a substituent, a C1-10 alkylthio group which can have a substituent, a C2-10 alkenyl group which can have a substituent, a C2-10 alkynyl group which can have a substituent, and a C7-10 aralkyl group which can have a substituent,
- in formula (III),
- X3 represents a C1-10 alkyl group which can have a substituent, a C1-10 alkoxy group which can have a substituent, a C1-10 alkylthio group which can have a substituent, or a C2-10 alkynyl group which can have a substituent.
6 more elements
A method of inhibit an organic cation transporter 3 (OCT3) containing:
- administrating an OCT3 inhibitor represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, as an active component, to an object to inhibit an OCT3,
- wherein
- in formula (I),
- R1 to R3, R5 and R6 can be the same or different, and
- each represent a hydrogen atom, a halogen atom, a C1-3 alkyl group, a C1-3 alkoxy group, a C1-3 alkylthio group, or a C1-3 halogenoalkyl group, and
- R4 represents any of the groups represented by formulae (II) to (III),
- in formula (II),
- X2 represents a C1-10 alkyl group which can have a substituent, a C1-10 alkoxy group which can have a substituent, a C1-10 alkylthio group which can have a substituent, a C2-10 alkenyl group which can have a substituent, a C2-10 alkynyl group which can have a substituent, a C6-10 aryl group which can have a substituent, or a C7-10 aralkyl group which can have a substituent,
- in formula (III),
- X3 represents a C1-10 alkyl group which can have a substituent, a C1-10 alkoxy group which can have a substituent, a C1-10 alkylthio group which can have a substituent, or a C2-10 alkynyl group which can have a substituent.
7 more elements
Dependencies are inferred from the claim text.